As of Apr 24
| -0.395 / -3.53%|
The 3 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 15.00, with a high estimate of 21.00 and a low estimate of 14.00. The median estimate represents a +38.76% increase from the last price of 10.81.
The current consensus among 4 polled investment analysts is to Buy stock in ZIOPHARM Oncology Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.